Roivant Sciences Ltd.
HealthcareNASDAQ:ROIV · NASDAQ Global Market
+$0.57 today
Vol 5.27M · Avg 5.63M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $1.4B |
| Short-term Investments | $2.9B |
| Receivables | $789.8M |
| Other Current | $81.9M |
| Total Current Assets | $5.2B |
| PP&E (Net) | $92.4M |
| Long-term Investments | $415.9M |
| Tax Assets | $19.4M |
| Other Non-current | $33.0M |
| Total Non-current Assets | $560.7M |
| Total Assets | $5.7B |
Analysis
Selected assets total $5.7B for Latest. The largest visible component is Short-term Investments at $2.9B, about 50.1% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.4B -47.6% | $2.7B -58.5% | $6.5B +289.8% | $1.7B -18.6% | $2.1B | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $2.9B +32.3% | $2.2B +40359.8% | $5.4M +7.1% | $5.0M | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $789.8M | $0 -100.0% | $82.8M +120.0% | $37.6M +459.2% | $6.7M | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 -100.0% | $35.3M +1176.7% | $2.8M | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $81.9M -27.7% | $113.2M +543.2% | $17.6M -13.9% | $20.4M -21.4% | $26.0M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $5.2B +3.3% | $5.0B -25.7% | $6.7B +274.3% | $1.8B -16.2% | $2.1B | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $92.4M -8.6% | $101.1M +53.3% | $66.0M -28.6% | $92.3M +6.2% | $86.9M | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 -100.0% | $137.8M -4.9% | $144.9M | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $415.9M +37.3% | $302.9M +22.3% | $247.8M -18.6% | $304.3M -6.6% | $325.8M | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $19.4M | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $33.0M +0.5% | $32.9M -16.0% | $39.1M -21.0% | $49.5M +91.6% | $25.8M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $560.7M +28.3% | $436.9M -11.0% | $490.7M -17.0% | $591.0M +34.7% | $438.6M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $5.7B +5.4% | $5.4B -24.7% | $7.2B +202.2% | $2.4B -7.6% | $2.6B | $13.3B | $11.9B | $10.6B |
| Account Payables | $18.0M -24.0% | $23.7M -55.5% | $53.2M +40.7% | $37.8M +9.4% | $34.6M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $11.1M +13.3% | $9.8M -18.0% | $12.0M -70.5% | $40.7M | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $45.7M +10882.9% | $416.0K -96.0% | $10.5M +1831.5% | $542.0K -23.4% | $708.0K | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 -100.0% | $1.2M -72.0% | $4.2M -66.5% | $12.4M +22.6% | $10.1M | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $119.1M +120.8% | $53.9M -37.2% | $85.9M +14.8% | $74.8M -10.9% | $84.0M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $281.2M +88.2% | $149.4M -44.0% | $266.8M -2.1% | $272.4M +47.8% | $184.4M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $0 | $0 -100.0% | $430.6M +14.7% | $375.5M +78.8% | $210.0M | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $19.4M | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 -100.0% | $13.7M | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $38.7M +287.3% | $10.0M -65.9% | $29.3M -63.6% | $80.6M +51.8% | $53.1M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $154.4M +53.9% | $100.3M -80.2% | $507.2M -0.5% | $509.6M +50.2% | $339.3M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $435.6M +74.4% | $249.7M -67.7% | $774.0M -1.0% | $782.0M +49.3% | $523.7M | $14.7B | $3.7B | $9.6B |
| Common Stock | $0 | $0 | $0 | $0 | $0 | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$501.8M -532.4% | $116.1M -79.9% | $576.2M +115.3% | -$3.8B -36.5% | -$2.8B | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $4.4M -53.8% | $9.4M +331.2% | -$4.1M -56.0% | -$2.6M -176.6% | -$946.0K | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $765.0M +53.1% | $499.6M +4.1% | $479.9M +6.7% | $449.8M +11.2% | $404.5M | $1.4B | $337.8M | $931.4M |
| Total Equity | $5.3B +2.0% | $5.2B -19.6% | $6.4B +301.1% | $1.6B -22.0% | $2.1B | $9.1B | $7.7B | $3.3B |
| Total Debt | $107.4M +7.3% | $100.2M -80.0% | $499.7M +3.8% | $481.4M +69.6% | $283.9M | $724.2M | $410.6M | $399.4M |
| Net Debt | -$1.3B +49.7% | -$2.6B +56.7% | -$6.0B -404.9% | -$1.2B +32.7% | -$1.8B | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Revolution Medicines, Inc.
NASDAQ:RVMD
$32.72B
Royalty Pharma plc
NASDAQ:RPRX
$23.72B
Exact Sciences Corporation
EXAS
$20.03B
Moderna, Inc.
NASDAQ:MRNA
$20.03B
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
$14.64B
Ascendis Pharma A/S
NASDAQ:ASND
$13.67B
BridgeBio Pharma, Inc.
NASDAQ:BBIO
$13.17B
Ionis Pharmaceuticals, Inc.
NASDAQ:IONS
$12.17B
Summit Therapeutics Inc.
NASDAQ:SMMT
$10.82B
Atrium Therapeutics, Inc.
NASDAQ:RNA
$210.23M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does ROIV have?
Roivant Sciences Ltd. (ROIV) reported $1.42B in cash and equivalents in fiscal 2025.
How much debt does ROIV carry?
Roivant Sciences Ltd. (ROIV) reported $107.44M of total debt, with net debt of -$1,315,652,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.